2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous...
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety profile in heavily pretreated patients with EGFR-mutated NSCLC who had developed resistance to EGFR TKI treatment SHANGHAI, Dec. 11, 2024 /PRNewswire/...